Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

Eli Lilly's diversified portfolio and high demand for its weight-loss drugs have pushed it to the top of Wall Street's list of top pharma stocks for 2024. Is now the time to buy?

Barchart

Eli Lilly Beefs Up Its Weight-Loss Marketing Efforts With New Direct-To-Consumer Site

Eli Lilly stepped up its marketing efforts for weight-loss drugs Thursday, launching a new website. Eli Lilly stock fell a fraction.

Investors Business Daily

Eli Lilly says obesity drugs not for 'cosmetic' use amid digital-sales push

Eli Lilly is looking to deliver its anti-obesity treatments directly to consumers while warning against their use for 'cosmetic' weight loss.

The Street

From analysis to the latest developments in health,
read the most diverse news in one place.

Insulin Now Available for $35 a Month for Many Americans

Insulin price caps from Eli Lilly, Novo Nordisk and Sanofi take effect this month.

Kiplinger

Eli Lilly, IBD Stock Of The Day, Strikes Bullish Pose After Closing A Key Buyout

Eli Lilly stock is Tuesday's IBD Stock Of The Day after the company wrapped its $1.4 billion takeover of Point Biopharma.

Investors Business Daily

Dow Jones Futures Fall To Start 2024; Tesla Deliveries Due As Rival Races Ahead

After a big 2023, the market rally looks strong heading into 2024. Tesla deliveries are due after key rivals reported.

Investors Business Daily

Structure Plummets 43% After Trailing Lilly In Obesity Treatment

Structure's potential rival to Lilly in weight-loss drugs missed expectations on Monday, and GPCR stock took an absolute beating.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Weight loss from Lilly’s Zepbound drug reversed after stopping treatment, according to study

‘They gain back about half the weight they had originally lost over a one-year period of time,’ professor says

The Independent UK

Eli Lilly Stock Skids On A Key New Finding For Its Obesity Drug, Zepbound

Eli Lilly stock skidded Monday after a new study showed patients who stopped taking its weight-loss drug slowly regained weight over a year.

Investors Business Daily

Eli Lilly slumps after disappointing Zepbound weight-loss-drug trial

Zepbound, which Eli Lilly had hoped would offset the slide in Trulicity sales, had mixed results in a major clinical trial.

The Street

Amphastar, Stock Of The Day, Breaks Out As It Sees Upside From Eli Lilly Deal

Amphastar is IBD Stock Of The Day as the biotech stock revs up marketing of Baqsimi, a drug purchased this year from Eli Lilly.

Investors Business Daily

Career advice from the CFOs of Dell, Eli Lilly, and Marriott—3 women who have each spent 20-plus years climbing the ladder at one company

As the CFO role continues to evolve, the leaders also explained the integral part of being an effective finance chief.

Fortune

Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review

The Dow Jones pushed higher, but the Nasdaq slipped despite strong software earnings and a Fed shift toward rate cuts. Tesla Cybertruck deliveries began.

Investors Business Daily

Eli Lilly’s CFO explains why the company’s newest weight-loss drug Zepbound will cost 20% less than the current options

Zepbound is expected to be available in the U.S. by the end of the year.

Fortune

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives

Novo Nordisk stock skidded Tuesday after Eli Lilly's weight-loss drug outperformed Novo's rival medication in a first-of-its-kind study.

Investors Business Daily

Eli Lilly Stock Nears Another Record As Drugmaker Enters The Weight-Loss Arena

Eli Lilly stock is Monday's IBD Stock Of The Day. Shares are forming a new flat base after the FDA approved Lilly's new weight-loss drug.

Investors Business Daily

Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning

Biogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started.

Investors Business Daily

Novo Nordisk Stock Skids — But These Weight-Loss Results Are 'Hard To Ignore'

Novo Nordisk stock slumped Monday despite unveiling promising test results for weight-loss drugs and diabetes development.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review

The stock market rally erased weekly gains as the major indexes ended long win streaks amid rebounding yields. Datadog led earnings winners.

WEKU

FDA approves Zepbound, a new obesity drug that will take on Wegovy

Eli Lilly said the obesity medicine, which helped adults in clinical studies lose about 20% of their body weight, will be available in the U.S. by the end of the year. The list price will be $1,060.

Investors Business Daily

Here's How Lilly Plans To Unseat Novo As The Weight-Loss Drugs Kingpin

The FDA approved a highly anticipated weight-loss drug from Eli Lilly on Wednesday. Eli Lilly stock popped on the approval news.

Investors Business Daily

Eli Lilly, Power Generators Lead Top S&P 500 Performers Monday

Eli Lilly was an S&P 500 top performer Monday, while energy plays were among the day's biggest winners and losers.

Investors Business Daily

Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners

Cathie Wood's flagship Ark Innovation ETF ARKK just had its best week ever thanks to Roku, DraftKings, Palantir and other huge winners on big news.

Fortune

Novo Nordisk isn’t alone: Sales of Wegovy rival Mounjaro explode as drugmaker Eli Lilly profits from Americans’ weight-loss craze

Drugs helping weight-loss like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro drove blockbuster sales for the pharma giants in the third quarter.

Investors Business Daily

Eli Lilly Smashes Forecasts As Mounjaro Sales Rocket 652%

Eli Lilly stock rose early Thursday after diabetes blockbuster Mounjaro helped the company beat sales expectations.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.